X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA SANOFI INDIA ALEMBIC PHARMA/
SANOFI INDIA
 
P/E (TTM) x 28.1 32.9 85.4% View Chart
P/BV x 6.4 6.3 102.3% View Chart
Dividend Yield % 0.7 1.4 51.0%  

Financials

 ALEMBIC PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-16
SANOFI INDIA
Dec-16
ALEMBIC PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs7924,560 17.4%   
Low Rs4434,400 10.1%   
Sales per share (Unadj.) Rs167.01,028.5 16.2%  
Earnings per share (Unadj.) Rs38.2129.0 29.6%  
Cash flow per share (Unadj.) Rs42.0186.0 22.6%  
Dividends per share (Unadj.) Rs4.0068.00 5.9%  
Dividend yield (eoy) %0.61.5 42.7%  
Book value per share (Unadj.) Rs84.9753.6 11.3%  
Shares outstanding (eoy) m188.5223.03 818.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.74.4 84.9%   
Avg P/E ratio x16.234.7 46.6%  
P/CF ratio (eoy) x14.724.1 61.0%  
Price / Book Value ratio x7.35.9 122.3%  
Dividend payout %10.552.7 19.9%   
Avg Mkt Cap Rs m116,383103,174 112.8%   
No. of employees `000NA3.6 0.0%   
Total wages/salary Rs m4,2143,592 117.3%   
Avg. sales/employee Rs ThNM6,537.7-  
Avg. wages/employee Rs ThNM991.4-  
Avg. net profit/employee Rs ThNM819.8-  
INCOME DATA
Net Sales Rs m31,48723,686 132.9%  
Other income Rs m55708 7.8%   
Total revenues Rs m31,54224,394 129.3%   
Gross profit Rs m10,0605,281 190.5%  
Depreciation Rs m7221,313 55.0%   
Interest Rs m3715 245.3%   
Profit before tax Rs m9,3564,661 200.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1601,691 127.7%   
Profit after tax Rs m7,1942,970 242.2%  
Gross profit margin %31.922.3 143.3%  
Effective tax rate %23.136.3 63.6%   
Net profit margin %22.812.5 182.2%  
BALANCE SHEET DATA
Current assets Rs m15,06615,673 96.1%   
Current liabilities Rs m7,6746,678 114.9%   
Net working cap to sales %23.538.0 61.8%  
Current ratio x2.02.3 83.6%  
Inventory Days Days6776 88.1%  
Debtors Days Days4122 182.1%  
Net fixed assets Rs m8,2378,098 101.7%   
Share capital Rs m377230 163.7%   
"Free" reserves Rs m15,41617,088 90.2%   
Net worth Rs m16,00517,356 92.2%   
Long term debt Rs m00-   
Total assets Rs m24,59425,400 96.8%  
Interest coverage x255.2311.7 81.9%   
Debt to equity ratio x00-  
Sales to assets ratio x1.30.9 137.3%   
Return on assets %29.411.8 250.2%  
Return on equity %44.917.1 262.7%  
Return on capital %58.726.9 217.8%  
Exports to sales %55.724.5 227.6%   
Imports to sales %10.428.0 37.3%   
Exports (fob) Rs m17,5515,801 302.5%   
Imports (cif) Rs m3,2836,627 49.5%   
Fx inflow Rs m17,8117,145 249.3%   
Fx outflow Rs m5,3186,846 77.7%   
Net fx Rs m12,493299 4,178.1%   
CASH FLOW
From Operations Rs m9,3043,226 288.4%  
From Investments Rs m-3,105-1,555 199.7%  
From Financial Activity Rs m-1,959-1,818 107.8%  
Net Cashflow Rs m4,240-147 -2,884.4%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 2.9 14.4 20.1%  
FIIs % 9.1 14.6 62.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.5 132.4%  
Shareholders   49,328 15,184 324.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   PLETHICO PHARMA  DIVIS LABORATORIES  FULFORD INDIA  NATCO PHARMA  AJANTA PHARMA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 5-YR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS